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Duojiao Wu1, Catherine M Rice3 and Xiangdong Wang1,2*Cancer is one of the commonest causes of patient death in
the clinic and a complex disease occurring in multiple
organs per system, multiple systems per organ, or both, in
the body. The poor diagnoses, therapies and prognoses of
the disease could be mainly due to the variation of sever-
ities, durations, locations, sensitivity and resistance against
drugs, cell differentiation and origin, and understanding of
pathogenesis. With increasing evidence that the interaction
and network between genes and proteins play an important
role in investigation of cancer molecular mechanisms, it is
necessary and important to introduce a new concept of
Systems Clinical Medicine into cancer research, to integrate
systems biology, clinical science, omics-based technology,
bioinformatics and computational science to improve diag-
nosis, therapies and prognosis of diseases. Cancer bioinfor-
matics is a critical and important part of the systems
clinical medicine in cancer and the core tool and approach
to carry out the investigations of cancer in systems clinical
medicine. “Thematic Series on Cancer Bioinformatics”
gather the strength of BMC Bioinformatics, BMC Cancer,
Genome Medicine and Journal of Clinical Bioinformatics to
headline the application of cancer bioinformatics for the de-
velopment of bioinformatics methods, network biomarkers
and precision medicine. The Series focuses on new devel-
opments in cancer bioinformatics and computational sys-
tems biology to explore the potential of clinical applications
and improve the outcomes of patients with cancer.Expectations of methodologies
Cancer bioinformatics is one of multiple ways to concen-
trate bioinformatics methods in cancer, according to the
specificity of disease metabolisms, signaling, communica-
tion, and proliferations. Clinical bioinformatics, an emer-
ging science combining clinical informatics, bioinformatics,* Correspondence: xiangdong.wang@clintransmed.org
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reproduction in any medium, provided the ormedical informatics, information technology, mathematics,
and omics science together [1], can be considered to be one
of critical elements addressing clinical relevant challenges
in early diagnosis, efficient therapies, and predictive prog-
nosis of patients with cancer. There is a need to develop
cancer bioinformatics-specific methodologies or introduce
new and advanced bioinformatics tools to answer the spe-
cific question of cancer. For example, the Semantic Web
technology was used to understand high throughput clin-
ical data and develop quantitative semantic models
retrieved from Corvus, a data warehouse which provides a
uniform interface to various forms of Omics data, based on
systematic biological knowledge and by application of
SPARQL endpoint [2]. Semantic models, containing gen-
omic, transcriptomic and epigenomic data from melanoma
samples with Gene Ontology data and regulatory networks
constructed from transcription factor binding information,
were applied for the interplay between a cell molecular
state and its response to anti-cancer therapy. Multivariate
assays, a process to characterize error introduced in the
assay results from the intrinsic error in sample preparation
and measurement of the contributing factors, were used to
help and guide clinicians understanding the application to
PAM50 centroid-based genomic predictors for breast can-
cer treatment plans and providing the uncertainty informa-
tion in a usable way [3].
The applicability, specificity, and integration of method-
ologies, software, computational tools, and databases which
can be used to explore the molecular mechanisms of cancer
and identify and validate novel biomarkers, network bio-
markers, and individualized medicine in cancer should be
seriously considered. miRTrail is an integrative tool for ana-
lyzing comprehensive interactions of genes and miRNAs
based on expression profiles to generate more robust and
reliable results on deregulated pathogenic processes. It was
suggested that miRTrail may open avenues for investigating
the regulatory interactions between genes and miRNAs for
human diseases, including cancer, by integrating informa-
tion on 20.000 genes, almost 1.000 miRNAs, and roughly
280.000 putative interactions [4]. It would be helpful to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regulatory interactions between genes and miRNAs with
clinical phenotypes, e.g. the variation of gene interactions
among tumor locations, phages, differentiations, patient
symptoms, or responses to therapies. Medical imaging
should be one of important factors to be considered in the
application of cancer bioinformatics, since the imaging in
clinical pathology, ultrasonic, computerized tomography,
nuclear magnetic resonance imaging, and positron emission
tomography is one of the most necessary and important
approaches in the “early and accurate” detection and diag-
nosis of cancer. Bioinformatic analyses of morphological
features of masses and other abnormalities in medical
images were initiated by selective extraction of target fea-
tures by mathematical morphology and enhancement of
the extracted features by two contrast modification techni-
ques [5]. The algorithm described by Haustein and Schu-
macher in the Thematic Series on Cancer Bioinformatics
in Journal of Clinical Bioinformatics [6] can simulate tumor
growth and detect the formation of some metastases in ad-
vance of clinical detection in cells, on basis of clinical breast
cancer data.
It may be a non-relative question or a future expectation
how experts in cancer bioinformatics can help clinicians
to establish the potential picture of gene or protein inter-
actions and mechanisms correlated with tumor-associated
shapes, densities, or locations. A Commentary by von der
Heyde and Beissbarth in the Thematic Series on Cancer
Bioinformatics in BMC Medicine [7] discusses the recent
insights into mechanisms of cetuximab resistance in head
and neck cancers resulting from novel analysis of the
EGFR pathway.
New strategies of biomarkers
Cancer bioinformatics is expected to play a more import-
ant role in the identification and validation of biomarkers,
specific to clinical phenotypes related to early diagnoses,
measurements to monitor the progress of the disease and
the response to therapy, and predictors for the improve-
ment of patient’s life quality. Of gene-, protein-, peptide-,
chemical- or physic-based variables in cancer, biomarkers
were investigated from a single one to multiple markers,
from the expression to functional indication, and from the
network to dynamic network. Network biomarkers as a
new type of biomarkers with protein-protein interactions
were investigated with the integration of knowledge on
protein annotations, interaction, and signaling pathway.
Alterations of network biomarkers can be monitored and
evaluated at different stages and time points during the
development of diseases, named dynamic network bio-
markers, as one of the new strategies. Dynamic network
biomarkers were expected to be correlated with clinical in-
formatics, including patient complaints, history, therapies,
clinical symptoms and signs, physician’s examinations,biochemical analyses, imaging profiles, pathologies and
other measurements [8].
Systems clinical medicine is recommended as one of
new strategies for the development of cancer biomarkers.
Systems clinical medicine is coined as the integration of
systems biology, clinical phenotypes, high-throughout
technologies, bioinformatics and computational science to
improve diagnosis, therapies and prognosis of diseases.
Cancer biomarkers should possess the characters of net-
works, dynamics, interactions, and specificities to disease
diagnosis, therapy and prognosis. Understanding the inter-
action between clinical informatics and bioinformatics is
the first and critical step to discover and develop the new
diagnostics and therapies for diseases. Such strategy has
been described in other diseases like acute rejection after
renal transplantation or lung diseases [9,10]. In brief,
human samples from clinical studies under clear and strict
criteria of participating recruitments are collected and har-
vested with an entire profile of clinical informatics trans-
lated from clinical descriptions. Gene and/or protein
profiles of defined samples are analyzed and dynamic net-
works and interactions between genes and/or proteins can
be figured out by bioinformatics and systems biology.
Selected disease-specific networks and dynamic net-
works of genes and/or proteins in patients are correlated
with each of clinical phenotypes by the computational
mode, to validate and optimize disease-special biomarkers.
However, a number of challenges in the application of
systems clinical medicine are encountered and need to be
overcome; e.g. the optimal system to translate the infor-
mation of clinical descriptions to clinical informatics,
bioinformatics analysis oriented with disease severity, dur-
ation, location, sensitivity to therapies, and progress, or
computational mode to integrate all elements from clinical
and high-throughout data for precision conclusions. It is
also a challenge to find out the variation and significance
between molecular networks, between networks of mole-
cules and clinical phenotypes, and between gene and/or
protein interactions, in addition to the expression of genes
and proteins. Cun and Fröhlich in the Thematic Series
on Cancer Bioinformatics in BMC Bioinformatics report
that incorporating protein network and interaction data
improve the ability to interpret gene signatures in a study
to stratify breast cancer patients, evidenced by findings
that R weighted Recursive Feature Elimination and aver-
age pathway expression were most effective at generating
interpretable signatures in those methods tested [11].
Monitoring and prediction of precision medicine
Systems cancer medicine has been proposed as a new strat-
egy towards realization of predictive, preventive, persona-
lized and participatory (P4) medicine [12-15]. Tian et al.
[15] recently proposed that a virtual cloud of billions of
data generated from high-throughout technologies in
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ease-perturbed networks in cells of the relevant organ in
the disease. Disease-perturbed molecular networks may in-
dicate the abnormality of early signals and the functioning,
to finally carry out P4 medicine in cancer. However, cancer
clinical bioinformatics is an important way to reach sys-
tems clinical medicine by combining clinical measurements
and signs with human cancer tissue-generated bioinformat-
ics, understanding clinical symptoms and signs, disease de-
velopment and progress, and therapeutic strategy, and
mapping relationships that integrate discrete elements that
collectively direct global function within a particular -omic
category, with clinical examinations, pathology, biochem-
ical analysis, imaging and therapies [1,8]. Ren and collea-
gues in the Thematic Series on Cancer Bioinformatics in
BMC Bioinformatics have developed an algorithm named
Optimization Tool for Clustering and Classification for
multiple types of measurements, including proteomic and
next generation sequencing data types [16]. Such method
could successfully and effectively discover class of unknown
cancer samples as class prediction in both breast cancer
and leukemia data sets.
Cancer bioinformatics plays an important role in moni-
toring and predicting the efficiency and effectiveness of the
precision medicine, which provides the safest and most
effective therapeutic strategy based on the gene and pro-
tein variations of each subject. The semantic heterogeneity
of the data generated from microarrays, proteomics, epi-
genetics and next generation sequencing, provided an
ontology-based solution for querying distributed databases
over service-oriented, model-driven infrastructures by inte-
grating molecular, pathology, radiology and clinical data in
an efficient manner [17]. A recent study performed a for-
ward-genetic screen guided by genomic analysis of human
hepatic cellular carcinoma, and found that a common gen-
etic alteration in liver cancer (11q13.3 amplification)
resulted in activation of FGF19 which caused the selective
sensitivity to FGF19 inhibition through subsequent analysis
with mouse models and RNAi [18]. It is expected to de-
velop accurate tools for delivering the right treatment to
the right patient in the right time, based on molecular net-
work characters of each patient’s tumor. Cancer bioinfor-
matics and systems biology are expected to improve
prevention, diagnosis and treatment through therapy de-
sign. The classical techniques of statistics and bioinfor-
matics for analysis of the genome, biological sequences,
large-scale ‘omic’ data sets and protein three-dimensional
structure could form an indispensable backbone for com-
putational cancer research [19].
In conclusion, cancer bioinformatics as an emerging
strategy is one of the most critical and useful approaches
to systems clinical medicine for clinical research and appli-
cations and improve the outcomes of patients with cancer.The Thematic Series on Cancer Bioinformatics provides
a unique and outstanding platform and opportunity for
scientists to integrate omics science, bioinformatics tools
and data, clinical research, disease-specific biomarkers, dy-
namic networks, with precision medicine, together fighting
cancer and improving the life quality of patients with
cancer.
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